2024-10-24-上交所-浙江九洲药业股份有限公司2024年第三季度报告_14页_412kb

浙江九洲药业股份有限公司 2024 年第三季度报告分析总结

一、[Financial Performance]

• Revenue: Net revenue for the third quarter decreased by 9.15% year-over-year to RMB 3,965,261,223.17, primarily impacted by reduced sales volume.
• Net Profit: Net profit attributable to shareholders fell by 54.80% year-over-year to RMB 155,888,065.39, attributed to factors including foreign exchange losses and increased financial expenses.
• ROE: Equity attributable to shareholders increased by 1.04% year-over-year from RMB 8,461,133,056.22 to RMB 8,549,162,888.63, though impacted by sector-wide fluctuations.

二、[Business Development]

• The company continued to focus on research and development and expanded its global presence by establishing wholly-owned subsidiaries in Japan and Germany, aiming to enhance market competitiveness and address healthcare needs.

三、[Financial Growth]

• Revenue for the third quarter of 2024 increased by 34.74% year-over-year from RMB 3,451.60B to RMB 3,965.26B, reflecting incremental market expansion.

四、[Strategic Adjustments]

• The company announced changes to its equity structure, including the disposal of its equity stake in Raybow Europe, signaling a new phase in market resource allocation.

五、[Risk Factors]

• A higher financial charge ratio in Q3 2024 raised concerns about the overall profitability of the company, indicating potential risks from operational and macroeconomic factors in the relevant markets.

💎 Summary: In the third quarter of 2024, the company continued to emphasize technology and R&D, though faced pressure on profitability due to increased expenditure. While maintaining a positive market stance, measures against financial risks need timely deployment.